Marcel Nijland
dr.
I work as a hematologist and my main focus is on patients with aggressive B-cell lymphomas and CNS lymphomas. My research is centered on the application of novel diagnostic and therapeutic strategies into clinical trials. These include imaging-studies like 18F-FDG-PET, Zr-Brentuximab-PET and Zr-atezolizumab-PET. In addition, I aim to implement novel strategies to measure minimal residual disease, and prognostic gene expression profiles in DLBCL. Linked to this I also focus on mutational analysis to study clonal evolution and prognostic / predictive values of mutations. These studies are carried out in a close collaboration with HOVON and other departments in the UMCG.
R-miniCHOP versus R-CHOP in elderly patients with diffuse large B-cell lymphoma: A propensity matched population-based study
Published in: American Journal of Hematology
Access to document
10.1002/ajh.27151
document
For elderly frail patients with diffuse large B-cell lymphoma (DLBCL), an attenuated chemo-immunotherapy strategy of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-miniCHOP) was introduced as a treatment option as from 2014 onward in the Netherlands. Although R-miniCHOP is more tolerable, reduction of chemotherapy could negatively affect survival compared to R-CHOP. The aim of this analysis was to assess survival of patients treated with R-miniCHOP compared to R-CHOP. DLBCL patients ≥65 years, newly diagnosed in 2014-2020, who received ≥1 cycle of R-miniCHOP or R-CHOP were identified in the Netherlands Cancer Registry,...
D Al-Sarayfi, M Brink, M E D Chamuleau, R Brouwer, R S van Rijn, D Issa, W Deenik, G Huls, R Mous, J S P Vermaat, A Diepstra, J M Zijlstra, T van Meerten, M Nijland
A MYC-rearrangement is a negative prognostic factor in stage II, but not in stage I diffuse large B-cell lymphoma
Published in: Blood cancer journal
Access to document
10.1038/s41408-023-00971-y
document
MYC oncogene rearrangements (MYC-R) negatively affect survival in patients with Ann Arbor stage III–IV diffuse large B-cell lymphoma (DLBCL), but their impact in limited stage (LS) I–II is unclear. Therefore, we assessed the impact of MYC-R on progression-free survival (PFS) and overall survival (OS) in LS DLBCL patients at the population level. We identified 1,434 LS DLBCL patients with known MYC-R status diagnosed between 2014 and 2020, who received R-CHOP(-like) regimens using the Netherlands Cancer Registry, with survival follow-up until February 2022. Stage I patients with (n =...
A. V. de Jonge, J. A.A. Bult, D. F.E. Karssing, M. Nijland, M. E.D. Chamuleau, M. Brink
R-CODOX-M/R-IVAC versus DA-EPOCH-R in patients with newly diagnosed Burkitt lymphoma (HOVON/SAKK): final results of a multicentre, phase 3, open-label, randomised trial
Published in: The Lancet Haematology
Access to document
10.1016/S2352-3026(23)00279-X
document
Background: Patients with newly diagnosed high-risk Burkitt lymphoma are treated with high-intensity immune-chemotherapy regimens such as R-CODOX-M/R-IVAC or with lower-intensity regimens such as DA-EPOCH-R. The aim of this study was to make a formal comparison between these regimens. Methods: This multicentre, phase 3, open-label, randomised study was done in 26 clinical centres in the Netherlands, Belgium, and Switzerland. Eligible patients were aged 18–75 years with newly diagnosed high-risk Burkitt lymphoma without CNS involvement. Patients were randomly assigned to two cycles of R-CODOX-M/R-IVAC (R-CODOX-M: rituximab 375 mg/m2 on day...
Martine E.D. Chamuleau, Frank Stenner, Dana A. Chitu, Urban Novak, Monique C. Minnema, Paul Geerts, Wendy B.C. Stevens, Thorsten Zenz, Gustaaf W. van Imhoff, Ka Lung Wu, Astrid M.P. Demandt, Marie Jose Kersten, Wim E. Terpstra, Lidwine W. Tick, Dries Deeren, Eric Van Den Neste, Michael Gregor, Hendrik Veelken, Lara H. Böhmer, Clemens B. CasparPim Mutsaers, Jeannine M. Refos, Robby Sewsaran, Liping Fu, Rianne L. Seefat, Carin A. Uyl-de Groot, Stefan Dirnhofer, Michiel Van Den Brand, Daphne de Jong, Marcel Nijland, Pieternella Lugtenburg
FDG-PET/CT discriminates between patients with and without lymphomas in primary Sjögren’s syndrome
Published in: Rheumatology
Access to document
10.1093/rheumatology/kead071
document
OBJECTIVES: To assess the usefulness of FDG-PET/CT 1) to discriminate between pSS patients with and without lymphomas and 2) to evaluate systemic disease activity in pSS. METHODS: ACR-EULAR-positive pSS patients who underwent FDG-PET/CT were included. Scans were visually evaluated and quantitative analysis was performed by measuring standardized uptake values (SUV) of salivary and lacrimal glands and systemic regions. ROC analyses were performed to find SUV cut-off values to discriminate between lymphoma and non-lymphoma. RESULTS: 26 of the 70 included patients were diagnosed with a pSS-associated lymphoma, mostly of...
Fixed-duration venetoclax plus obinutuzumab improves quality of life and geriatric impairments in FCR-unfit patients with CLL
Published in: Blood
Access to document
10.1182/blood.2023020195
document
Chronic lymphocytic leukemia (CLL)–related symptoms and morbidity related to the advanced age at diagnosis impairs the well-being of older adult patients. Therefore, it is essential to tailor treatment according to geriatric characteristics and aim for an improvement in health-related quality of life (HRQoL) as a primary treatment goal. In the HOVON139/GiVe trial, 12 cycles of fixed-duration venetoclax plus obinutuzumab (Ven-O) were shown to be effective and tolerable in FCR (fludarabine, cyclophosphamide, rituximab)-unfit patients with CLL (n = 67). However, prolonged venetoclax exposure as consolidation treatment led to increased...
HOVON CLL Working Group, Lina van der Straten, Claudia A.M. Stege, Sabina Kersting, Kazem Nasserinejad, Julie Dubois, Johan A. Dobber, Clemens H.M. Mellink, Anne Marie F. van der Kevie-Kersemaekers, Ludo M. Evers, Fransien de Boer, Harry R. Koene, John Schreurs, Marjolein van der Klift, Gerjo A. Velders, Ellen van der Spek, Hanneke M. van der Straaten, Mels Hoogendoorn, Michel van Gelder, Eduardus F.M. PosthumaHein P.J. Visser, I. Houtenbos, Cecile A.M. Idink, D. E. Issa, Ellen C. Dompeling, Henk C.T. van Zaanen, J. Hendrik Veelken, Henriette Levenga, Lidwine W. Tick, Wim E. Terpstra, Sanne H. Tonino, Peter E. Westerweel, Anton W. Langerak, A. P. Kater, Mark David Levin